ILC Dover, Inc. (“ILC Dover”, “ILC” or the “Company”), a leading designer and manufacturer of high-performance materials for life critical and primarily life sciences-based applications, today announced the acquisition of KSE Scientific (“KSE”), a sterile solutions manufacturer which specializes in the production of Water for Injection (WFI) and related media and buffer solutions for biopharma, cell & gene therapy, tissue banking and medical device end-markets. Founded in 2000 and headquartered in Durham, North Carolina, KSE has transformed into a leading supplier of sterile consumable products and will continue to operate under its own brand.
“Under the leadership of founder James Lally, KSE has built an exciting platform and shares in ILC Dover’s culture in providing consistent, repeatable and high-quality service to customers,” said Corey Walker, CEO of ILC Dover. “The acquisition accelerates ILC’s trajectory of becoming a market leader across the biopharmaceutical workflow and I look forward to working with the KSE team to further support the growth of both businesses.”
ILC and KSE have highly complementary product offerings and the combination creates significant growth opportunities by offering a broader and more integrated workflow solution to customers. Following the transaction, ILC will be able to provide custom cell-culture and bioprocess solutions within its own liquid bag containment solutions to better serve its customers within biopharma, cell & gene therapy, and related life sciences end markets.
“Our team at KSE Scientific has built a specialized WFI product offering for the life sciences end market, and we are excited to continue to grow and innovate our market leading capabilities in partnership with ILC Dover. The combination with ILC Dover provides KSE with a clear path to expand into biopharmaceutical end markets.” said James Lally, founder of KSE, who will remain with the Company. “I look forward to continuing to lead KSE as a part of ILC Dover, and remain committed to our deep heritage of delivering best-in-class service and tremendous product value to our existing customer base.”
Following the acquisition of Flexan earlier this year, KSE is the third acquisition ILC Dover has completed since announcing a partnership with New Mountain Capital in early 2020. The acquisition will continue to grow ILC Dover’s life sciences solutions for its global customer base, including for the pharmaceutical, biopharmaceutical, cell & gene therapy and medical device end markets.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace
